Tue 9/19/2017 12:59 ET
DJIA22377.0345.680.20%SOLAR22.490.220.99%GOLD1309.701.050.08%Shanghai3136.7734.501.10%
S&P 5002507.173.260.13%BANKS25.260.200.80%OIL49.480.430.86%Nikkei20299.38397.871.96%
NASDAQ6460.656.010.09%SEMI92.740.380.41%US/EU1.200.000.17%Futures2505.002.250.09%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Stocks For A Different Jungle    If it belongs at the Pit it doesn't belong here.

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search
  
From: blacksheep (Rep: 307)Date: 06/02/2017 07:14
Forum: Stocks For A Different Jungle - Msg #19108Thread #673930646 (Rec: 0)
Significant Insider buying.

One biotechnology player that insiders are snapping up a huge amount of stock in is Bioverativ (BIVV) , which focuses on the research, discovery, development, and commercialization of therapies for the treatment of hemophilia and other blood disorders.

Bioverativ has a market cap of $5.8 billion. This stock trades at a reasonable valuation, with a forward price-to-earnings of 16.8. Its estimated growth rate for this year 27.8%, and for next year it's pegged at 17%. This is a cash-rich company, since its total cash position is $358.70 million and its total debt is zero.

A director just bought 920,000 shares, or $51.30 million worth of stock, at $54.16 to $57.21 per share.

If you're bullish on Bioverativ, then I would look for long-biased trades as long as this stock is trending above key support at $51.06 and then once it breaks out above resistance at $57.83 to its all-time high of $59.50 with volume near or above its three-month average of 1.37 million shares. Some possible upside targets off that breakout are $65 to $70, or even $75 a share.



What would you like to do? Message: Endorse | Bookmark | Report AbuseUser blacksheep: Reward | Watch | Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.